225 related articles for article (PubMed ID: 22903545)
1. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
[TBL] [Abstract][Full Text] [Related]
2. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
3. BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.
Yu X; Zheng Y; Mao R; Su Z; Zhang J
Front Immunol; 2019; 10():617. PubMed ID: 30984188
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.
Zhang M; Howard K; Winters A; Steavenson S; Anderson S; Smelt S; Doellgast G; Sheelo C; Stevens J; Kim H; Hamburger A; Sein A; Caughey DJ; Lee F; Hsu H; Siu G; Byrne FR
Clin Exp Immunol; 2011 Jan; 163(1):77-87. PubMed ID: 21078085
[TBL] [Abstract][Full Text] [Related]
5. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML
Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526
[TBL] [Abstract][Full Text] [Related]
6. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
[TBL] [Abstract][Full Text] [Related]
7. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
[TBL] [Abstract][Full Text] [Related]
8. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
9. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
10. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
11. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
13. B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis.
Ishida W; Fukuda K; Kajisako M; Sumi T; Matsuda H; Yagita H; Fukushima A
Graefes Arch Clin Exp Ophthalmol; 2012 Feb; 250(2):289-95. PubMed ID: 21779950
[TBL] [Abstract][Full Text] [Related]
14. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
15. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
16. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
17. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.
Gertner-Dardenne J; Fauriat C; Orlanducci F; Thibult ML; Pastor S; Fitzgibbon J; Bouabdallah R; Xerri L; Olive D
Blood; 2013 Aug; 122(6):922-31. PubMed ID: 23692853
[TBL] [Abstract][Full Text] [Related]
18. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
19. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
20. BTLA inhibition has a dominant role in the
Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
Front Immunol; 2022; 13():956694. PubMed ID: 36081508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]